NCT04706221 is a NA clinical trial of CM-1500 in Blood Loss, sponsored by Zynex Monitoring Solutions.

Who is sponsoring NCT04706221?

NCT04706221 is sponsored by Zynex Monitoring Solutions.

What drugs are being tested in NCT04706221?

Interventions in NCT04706221: CM-1500.

What condition does NCT04706221 study?

NCT04706221 studies Blood Loss.

Is NCT04706221 still recruiting?

NCT04706221 is currently completed. Last updated 27 March 2024.

Are results published for NCT04706221?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-03-27 · How we verify

NCT04706221

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Evaluation of the CM-1500 in Postoperative Surgery Patients

Completed NA Results posted Last updated 27 March 2024

What this trial tests

NA trial testing CM-1500 in Blood Loss in 200 participants. Completed in 29 November 2021.

Timeline

15 January 2021

Primary endpoint
29 November 2021

29 November 2021

Quick facts

Lead sponsor	Zynex Monitoring Solutions
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	200
Start date	15 January 2021
Primary completion	29 November 2021
Estimated completion	29 November 2021
Sites	1 location across United States

Drugs / interventions tested

CM-1500

Conditions studied

Blood Loss — all drugs for Blood Loss →

Sponsor

Zynex Monitoring Solutions

Who can join

Adults 18 to 100, any sex, with Blood Loss. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Relative Index Change During PACU Stay Primary · Length of PACU Stay (Range: 46 to 353 minutes)

The primary objective is to evaluate changes in the Relative Index (RI) in post-abdominal or pelvic surgery patients (Laparoscopic or Open). The CM-1500 monitors parameters which are indicative of relative changes in fluid volume in adult patients. The Relative Index is an investigational value which utilizes proprietary algorithms to combine the relative changes of each measured parameter into a single value. The Relative Index is graded on a scale where 100 indicates a patient's baseline, and changes up or down from the baseline could be used as potential indicators of fluid gain or loss rel

Group	Value	95% CI
Blood Volume Monitoring - Open Surgery	-2.01	± 4.00
Blood Volume Monitoring - Laparoscopic Surgery	-1.32	± 3.11

Sponsor's own description

The primary objective is to evaluate the the changes in the Relative Index in post abdominal or pelvic surgery patients on the Cardiac Monitor Model CM-1500.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of CM-1500

Trials testing the same drug.

NCT05125848 — Clinical Evaluation of the CM-1500 During Hemodialysis · NA · completed
NCT05012462 — Clinical Evaluation of the CM-1500 During Apheresis Blood Donation · NA · completed

Other recruiting trials for Blood Loss

Currently open trials in the same condition.

NCT07526311 — Reducing Blood Loss During Myomectomy:Uterine Artery Ligation Vs Pericervical Tourniquet · NA · recruiting
NCT07089251 — The Perioperative Outcome of Epinephrine Infusion and Tranexamic Acid in Knee Arthroplasty Surgery · Phase 4 · recruiting
NCT05488457 — Oxytocin Pharmacokinetics and Pharmacodynamics · Phase 2 · recruiting
NCT06802874 — Maternal-fetal Outcomes of Genital Blood Loss Beyond 18 Weeks of Pregnancy · recruiting
NCT06903299 — Prospective Investigation of Intra-Articular Tranexamic Acid Use in Elective Hip Arthroplasty · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04706221 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zynex Monitoring Solutions
Last refreshed: 27 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04706221.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing